Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CAR T-cell therapy bb2121 performs well in phase 1 trial of refractory multiple myeloma

Publish date:: April 30, 2019

Key clinical point: CAR T-cell therapy bb2121, which targets B-cell maturation agent (BCMA), appears safe for treating patients with refractory multiple myeloma.

Major finding: The objective response rate was 85%.

Study details: A phase 1 trial involving 33 patients with refractory multiple myeloma.

Disclosures: The study was funded by Bluebird Bio and Celgene. The investigators disclosed financial relationships with Bluebird and other drug companies.

Citation:

Raje N et al. New Engl J Med. 2019 May 1. doi: 10.1056/NEJMoa1817226.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lymphoma & Plasma Cell Disorders

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,